Hyperkalaemia in Cardiological Patients: New Solutions for an Old Problem.

Manuela Benvenuto, Giulio Binaghi, Carmine Riccio, Maria Denitza Tinti, Pier Luigi Temporelli, Alessandro Maloberti, Fabrizio Oliva, Maurizio Giuseppe Abrignani, Marco Marini, Mauro Gori, Massimo Grimaldi, Furio Colivicchi, Massimo Iacoviello, Edoardo Gronda, Domenico Gabrielli, Arturo Cesaro

Journal: Cardiovascular drugs and therapy 2025;39(4):857-874

PMID: 38289453

Abstract

Hyperkalaemia is one of the most common electrolyte disorders in patients with cardiovascular disease (CVD). The true burden of hyperkalaemia in the real-world setting can be difficult to assess, but in population-based cohort studies up to 4 in 10 patients developed hyperkalaemia. In addition to drugs interfering with potassium metabolism and food intake, several conditions can cause or worsen hyperkalaemia, such as advanced age, diabetes, and chronic kidney disease. Mortality, cardiovascular morbidity, and hospitalisation are higher in patients with hyperkalaemia. Hyperkalaemia represents a major contraindication or a withholding cause for disease-modifying therapies like renin-angiotensin-aldosterone inhibitors (RAASi), mainly mineralocorticoid receptor antagonists. Hyperkalaemia can be also classified as acute and chronic, according to the onset. Acute hyperkalaemia is often a life-threatening emergency requiring immediate treatment to avoid lethal arrhythmias. Therapy goal is cell membrane stabilisation by calcium administration, cellular intake, shift of extracellular potassium to the intracellular space (insulin, beta-adrenergic agents, sodium bicarbonate), and increased elimination with diuretics or dialysis. Chronic hyperkalaemia was often managed with dietary counselling to prevent potassium-rich food intake and tapering of potassium-increasing drugs, mostly RAASi. Sodium polystyrene sulphonate, a potassium binder, was the only therapeutic option. Recently, new drugs such as patiromer and sodium zirconium cyclosilicate give new opportunities for the treatment of hyperkalaemia, as they proved to be safe, well tolerated, and effective. Aim of this review is to describe the burden of hyperkalaemia in cardiovascular patients, its direct and indirect effects, and the therapeutic options now available in the acute and chronic setting.

© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Address: Chairperson Working Group On Cardiological Chronicity ANMCO, Cardiology Unit, P. Borsellino Hospital, ASP Trapani, M.D., Via F. Crispi 6, 91025, Marsala, Italy. [email protected].; Chairperson Cardiorenal and Metabolic Working Group ANMCO; Medicine and Medicine Sub-Specialties Department, Cardio Renal Program, UOC Nephrology, Dialysis and Adult Renal Transplant Program, IRCCS Ca' Granda Foundation, Ospedale Maggiore Policlinico, Milan, Italy.; Chairperson Working Group On Heart Failure ANMCO; Department, Cardiology-ICCU, Marche University Hospital, Ancona, Italy.; Cardiology Division, Cardiovascular Department, ASST Papa Giovanni XXIII, Bergamo, Italy.; Cardiology Unit, Ospedali Riuniti, Foggia, Italy.; Division of Cardiac Rehabilitation, ICS Maugeri, IRCCS Gattico-Veruno, Piedmont, Italy.; Cardiology Unit, Ospedale Civile G. Mazzini, Teramo, Italy.; Cardiology Unit, ARNAS G. Brotzu, Cagliari, Italy.; Cardiology Unit, AORN Sant'Anna E San Sebastiano, Campania University "L. Vanvitelli," Napoli, Caserta, Italy.; Cardiotoracovascular Department, ASST GOM Niguarda Cà Granda, "A. De Gasperis, Cardiology 4, Milan, Italy.; Cardiology-ICCU UOC, A.O. San Camillo Forlanini, Rome, Italy.; Cardiovascular Department, Post-Acute Patient Follow-Up UOSD, AORN, Sant' Anna and San Sebastiano, Caserta, Italy.; Clinical and Rehabilitative Cardiology UOC, ASL Roma 1, P.O. San Filippo Neri, Rome, Italy.; Cardiology UOC, Ospedale Miulli, Acquaviva Delle Fonti, Bari, Italy.; Cardiology-ICCU UOC, A.O. San Camillo Forlanini, Rome, Italy.; Heart Care Foundation, Florence, Italy.; Cardiotoracovascular Department "A. De Gasperis, ASST GOM Niguarda Cà Granda, ICCU, Cardiology 1 - Haemodynamics UOC, Milan, Italy.; ANMCO, Florence, Italy.

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.